{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:45:07Z","timestamp":1795031107708,"version":"4.10.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the phase 3 SUNRISE trial conducted in a predominantly Asian population with chronic migraine (CM), eptinezumab (100 or 300 mg) met the primary and all key secondary endpoints and was well-tolerated. The open-label SUNSET extension trial was conducted in Japanese participants from SUNRISE and evaluated long-term safety, tolerability, and effectiveness of eptinezumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After completing the 12-week double-blind period of SUNRISE, the first 160 Japanese participants enrolled in SUNSET and 159 received eptinezumab every 12\u2009weeks for 60\u2009weeks. At the SUNSET baseline visit (also SUNRISE Week 12), all participants received an infusion of eptinezumab 100\u2009mg. For those with a\u2009&lt;\u200950% reduction in monthly migraine days (MMDs) during SUNSET Weeks 1\u201312 relative to baseline values obtained in SUNRISE, the dose of eptinezumab was increased to 300\u2009mg at SUNSET Week 12. The primary outcome was safety and tolerability (based on treatment-emergent adverse events); secondary outcomes were maintenance of migraine-preventive effect and impact on health-related quality of life (e.g, Patient Global Impression of Change [PGIC], patient-identified most bothersome symptom [PI-MBS], and Migraine-specific Work Productivity and Activity Impairment [WPAI:M]). Baseline values reported are from the SUNRISE trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 159 treated participants, 141 (88.7%) completed SUNSET. Evaluable participants were mostly female (87.4%), with a mean age of 41.9\u2009years and a mean of 17.1 baseline MMDs. No new safety signals were identified, and few participants had a serious adverse event (3.1%), event leading to withdrawal (4.4%), or infusion interruption\/termination (5.0%). MMD reductions from the lead-in placebo-controlled trial were maintained during SUNSET, and just over 35% of participants had \u226550% reduction in MMDs from Week 24 onwards. PGIC scores showed that ~50% of participants were very much or much improved from Week 24 onwards. From the lead-in placebo-controlled trial, PI-MBS scores and WPAI:M domain scores for presenteeism, work productivity loss, and activity impairment showed sustained improvement over 60\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term (60\u2009weeks) treatment with eptinezumab was found to maintain reductions in migraine frequency and severity from the placebo-controlled lead-in trial, with no new safety concerns. These results confirm the effectiveness of eptinezumab in Japanese participants with CM to reduce the burden of migraine and improve the ability to undertake daily life activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (Identifier: NCT05064371; date of registration: September 22, 2021)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02214-w","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:37:03Z","timestamp":1763786223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-4754","authenticated-orcid":false,"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-3012","authenticated-orcid":false,"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidsel","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Krog","family":"Josiassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-807X","authenticated-orcid":false,"given":"Aur\u00e9lia","family":"Mittoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"10100","key":"2214_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/s0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211\u20131259. https:\/\/doi.org\/10.1016\/s0140-6736(17)32154-2","journal-title":"Lancet"},{"issue":"1","key":"2214_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther 14(1):297\u2013315. https:\/\/doi.org\/10.1007\/s40122-024-00690-7","journal-title":"Pain Ther"},{"key":"2214_CR3","unstructured":"Current Population Estimates (2021 [Available from: Statistics Bureau of Japan. https:\/\/www.stat.go.jp\/english\/data\/jinsui\/2021np\/index.html. as of October 1, 2021"},{"issue":"1","key":"2214_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40120-023-00569-3","volume":"13","author":"E Awaki","year":"2024","unstructured":"Awaki E, Takeshima T, Matsumori Y, Hirata K, Miyazaki N, Takemura R et al (2024) Impact of migraine on daily life: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther 13(1):165\u2013182. https:\/\/doi.org\/10.1007\/s40120-023-00569-3","journal-title":"Neurol Ther"},{"issue":"1","key":"2214_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, Ishii R, Hamakawa M, Tanizawa Y et al (2025) The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd study. Neurol Ther 14(1):335\u2013356. https:\/\/doi.org\/10.1007\/s40120-024-00690-x","journal-title":"Neurol Ther"},{"issue":"1","key":"2214_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH et al (2022) Burden of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and care of MigrainE (OVERCOME [Japan]) study. Neurol Ther 11(1):205\u2013222. https:\/\/doi.org\/10.1007\/s40120-021-00305-9","journal-title":"Neurol Ther"},{"issue":"1","key":"2214_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T (2020) Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain 21(1):110. https:\/\/doi.org\/10.1186\/s10194-020-01180-9","journal-title":"J Headache Pain"},{"issue":"11","key":"2214_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM et al (2021) Comprehensive population-based survey of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and care of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin 37(11):1945\u20131955. https:\/\/doi.org\/10.1080\/03007995.2021.1971179","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2214_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s10194-022-01439-3","volume":"23","author":"F Sakai","year":"2022","unstructured":"Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H et al (2022) A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J Headache Pain 23(1):70. https:\/\/doi.org\/10.1186\/s10194-022-01439-3","journal-title":"J Headache Pain"},{"issue":"1","key":"2214_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20(1):111. https:\/\/doi.org\/10.1186\/s10194-019-1062-4","journal-title":"J Headache Pain"},{"key":"2214_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.70042","author":"N Araki","year":"2025","unstructured":"Araki N, Takeshima T, Igarashi H, Shimizu T, Shibata M, Tatsumoto M et al (2025) Clinical practice guideline for headache disorders 2021. Neurol Clin Neurosci. https:\/\/doi.org\/10.1111\/ncn3.70042","journal-title":"Neurol And Clin Neurosci"},{"issue":"1","key":"2214_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20(1):68. https:\/\/doi.org\/10.1186\/s10194-019-1012-1","journal-title":"J Headache Pain"},{"issue":"1","key":"2214_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67.  https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"4","key":"2214_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64(4):333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"issue":"1","key":"2214_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N (2024) Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain 25(1):19. https:\/\/doi.org\/10.1186\/s10194-024-01722-5","journal-title":"J Headache Pain"},{"issue":"7","key":"2214_CR16","doi-asserted-by":"publisher","first-page":"e3547","DOI":"10.1002\/brb3.3547","volume":"14","author":"H Igarashi","year":"2024","unstructured":"Igarashi H, Komori M, Ueda K, Zagar AJ, Jaffe DH, Matsumori Y et al (2024) Underrecognition of migraine-related stigmatizing attitudes and social burden: results of the OVERCOME Japan study. Brain Behav 14(7):e3547. https:\/\/doi.org\/10.1002\/brb3.3547","journal-title":"Brain Behav"},{"issue":"12","key":"2214_CR17","doi-asserted-by":"publisher","first-page":"e0315610","DOI":"10.1371\/journal.pone.0315610","volume":"19","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Togo K, Yoshikawa R, Iijima M (2024) Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: insights from a retrospective cohort study using a Japanese claims database. PLoS One 19(12):e0315610. https:\/\/doi.org\/10.1371\/journal.pone.0315610","journal-title":"PLoS One"},{"issue":"1","key":"2214_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17(1):15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x","journal-title":"Cephalalgia"},{"key":"2214_CR19","doi-asserted-by":"publisher","first-page":"1355877","DOI":"10.3389\/fneur.2024.1355877","volume":"15","author":"P Irimia","year":"2024","unstructured":"Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, Lainez JM (2024) Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 15:1355877. https:\/\/doi.org\/10.3389\/fneur.2024.1355877","journal-title":"Front Neurol"},{"issue":"3","key":"2214_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"2214_CR21","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e77. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"1","key":"2214_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR et al (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"issue":"7","key":"2214_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al. (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5","journal-title":"The Lancet Neurol"},{"issue":"1","key":"2214_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-022-02774-3","volume":"22","author":"A Blumenfeld","year":"2022","unstructured":"Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R (2022) Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol 22(1):251. https:\/\/doi.org\/10.1186\/s12883-022-02774-3","journal-title":"BMC Neurol"},{"issue":"1","key":"2214_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-024-01764-9","volume":"25","author":"C Argoff","year":"2024","unstructured":"Argoff C, Herzog SP, Smith RM, Kotak SV, Sopina L, Saltarska Y et al (2024) Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. J Headache Pain 25(1):65. https:\/\/doi.org\/10.1186\/s10194-024-01764-9","journal-title":"J Headache Pain"},{"issue":"4","key":"2214_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/ene.15670","volume":"30","author":"PJ Goadsby","year":"2023","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2023) Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol 30(4):1089\u20131098. https:\/\/doi.org\/10.1111\/ene.15670","journal-title":"Eur J Neurol"},{"issue":"1","key":"2214_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s41687-024-00813-w","volume":"8","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Awad SF, Rae-Espinoza H, Regnier SA, Lee XY, Goadsby PJ (2024) Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial. J Patient Rep Outcomes 8(1):146. https:\/\/doi.org\/10.1186\/s41687-024-00813-w","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"2214_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00415-024-12809-z","volume":"272","author":"SJ Tepper","year":"2024","unstructured":"Tepper SJ, Diamond ML, Hirman J, Asher D, Fiore D, Cady R (2024) Eptinezumab treatment was associated with longer interictal headache\/migraine periods which corresponded to greater improvements in patient-reported quality of life measures. J Neurol 272(1):4. https:\/\/doi.org\/10.1007\/s00415-024-12809-z","journal-title":"J Neurol"},{"key":"2214_CR29","doi-asserted-by":"publisher","unstructured":"Yu S, Matsumori Y, Kim B-K, Gryglas-Dworak A, Giorgadze G, Pozo-Rosich P et al (2025) Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: results of the randomized, double-blind, placebo-controlled SUNRISE trial. Cephalalgia 45(10):3331024251386095. https:\/\/doi.org\/10.1177\/03331024251386095","DOI":"10.1177\/03331024251386095"},{"issue":"3","key":"2214_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"1","key":"2214_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"12","key":"2214_CR32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168(12):1266\u20131277. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111704","journal-title":"Am J Psychiatry"},{"key":"2214_CR33","volume-title":"Public health Service, alcohol, drug abuse, and mental health administration","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: U.S. Department of Health, Education, and Welfare. In: Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs"},{"issue":"5","key":"2214_CR34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R (2021) Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache 61(5):766\u2013776. https:\/\/doi.org\/10.1111\/head.14120","journal-title":"Headache"},{"issue":"6","key":"2214_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/head.14295","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Goadsby PJ, Dodick DW, McGinley JS, Houts CR, Wirth RJ et al (2022) Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. Headache 62(6):690\u2013699. https:\/\/doi.org\/10.1111\/head.14295","journal-title":"Headache"},{"issue":"8","key":"2214_CR36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Je W, Jr., Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Qual Life Res"},{"issue":"10","key":"2214_CR37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10):1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"issue":"4","key":"2214_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache 38(4):295\u2013302. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804295.x","journal-title":"Headache"},{"issue":"5","key":"2214_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"key":"2214_CR40","unstructured":"WPAI:Migraine. Reilly Associates (2024). Updated September 2024. Available from: http:\/\/www.reillyassociates.net\/WPAI_Translations-6.html."},{"issue":"1","key":"2214_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22(1):16. https:\/\/doi.org\/10.1186\/s10194-021-01227-5","journal-title":"J Headache Pain"},{"issue":"1","key":"2214_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J et al (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-2) study. J Headache Pain 21(1):120. https:\/\/doi.org\/10.1186\/s10194-020-01186-3","journal-title":"J Headache Pain"},{"issue":"7","key":"2214_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/head.14737","volume":"64","author":"YJ Zhao","year":"2024","unstructured":"Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ et al (2024) A real-world prospective observational study of eptinezumab in Asian patients with migraine. Headache 64(7):810\u2013824. https:\/\/doi.org\/10.1111\/head.14737","journal-title":"Headache"},{"issue":"1","key":"2214_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-022-01521-w","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain 23(1):153. https:\/\/doi.org\/10.1186\/s10194-022-01521-w","journal-title":"J Headache Pain"},{"issue":"7","key":"2214_CR45","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u20131101. https:\/\/doi.org\/10.1111\/head.14169","journal-title":"Headache"},{"issue":"10","key":"2214_CR46","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1080\/03007995.2020.1815181","volume":"36","author":"CP Yang","year":"2020","unstructured":"Yang CP, Lee CF, Dell\u2019agnello G, Hundemer HP, Lipsius S, Wang SJ (2020) Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine. Curr Med Res Opin 36(10):1653\u20131666. https:\/\/doi.org\/10.1080\/03007995.2020.1815181","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2214_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T et al (2022) A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 23(1):146. https:\/\/doi.org\/10.1186\/s10194-022-01514-9","journal-title":"J Headache Pain"},{"issue":"8","key":"2214_CR48","doi-asserted-by":"publisher","first-page":"e068616","DOI":"10.1136\/bmjopen-2022-068616","volume":"13","author":"K Hirata","year":"2023","unstructured":"Hirata K, Takeshima T, Sakai F, Numachi Y, Yoshida R, Koukakis R et al (2023) Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open 13(8):e068616. https:\/\/doi.org\/10.1136\/bmjopen-2022-068616","journal-title":"BMJ Open"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02214-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:19:40Z","timestamp":1781615980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02214-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2214"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02214-w","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was designed in accordance with the Declaration of Helsinki and was conducted in compliance with the protocol, Good Clinical Practice guidelines, and all applicable regulatory requirements. The trial was approved by the Ethics Committee or Institutional Review Board at each site. All participants provided written informed consent prior to trial participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Takao Takeshima is an advisor to Hedgehog MedTech, Inc. and Sawai Pharmaceutical Co., Ltd. Daisuke Danno serves on the advisory boards of Amgen, Daiichi Sankyo, Eli Lilly, Lundbeck, Pfizer, and Otsuka and received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka. Noboru Imai received speaker honoraria from Amgen, Daiichi Sankyo, Eli Lilly, and Otsuka. Keisuke Suzuki has received lecture fees from Eli Lilly Japan, Daiichi Sankyo, Amgen, and Otsuka Pharmaceutical Co., Ltd. Anders Ettrup, Sidsel Jensen, Mette Krog Josiassen, and Aur\u00e9lia Mittoux are all full-time employees of H. Lundbeck A\/S. Mette Krog Josiassen owns stock or stock options in H. Lundbeck A\/S. Yasuhiko Matsumori reports personal consultancy fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}